ImmunityBio, Inc. IBRX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
4/9
Piotroski F — financial health
-24.85
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $113.3M | -$351.4M | — | -$308.8M | -$500.5M |
| 2024 | $14.7M | -$413.6M | — | -$398.1M | -$488.1M |
| 2023 | $622,000 | -$583.2M | — | -$397.3M | -$585.9M |
| 2022 | $240,000 | -$416.6M | — | -$415.7M | -$449.8M |
| 2021 | $934,000 | -$346.8M | — | -$308.0M | -$243.9M |
| 2020 | $605,000 | -$221.9M | — | -$173.4M | -$118.5M |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -24.85 (distress)
- Working capital / assets 0.504
- Retained earnings / assets -7.425
- EBIT / assets -0.51
- Equity / liabilities -0.5
Source: SEC EDGAR filings · CIK 0001326110 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.